^
    1d
    Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. (PubMed, Blood Neoplasia)
    In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.
    Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    1d
    Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia. (PubMed, Blood Neoplasia)
    Our study identified cellular and molecular biomarkers, notably CD56, that predict resistance to Rux + Ven, but further work is needed to understand and validate their effect in AML. This trial was registered at www.clinicaltrials.gov as #NCT03874052.
    Clinical • P1 data • Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • ITGAM (Integrin, alpha M)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)
    1d
    PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis. (PubMed, Am J Cancer Res)
    We identify a link between IL-6 expression and PIM1 expression and activity in human ccRCC tumors and cell lines. Our work provides evidence that targeting an IL-6/JAK/STAT/PIM1 axis may be a viable therapeutic strategy for patients with PIM1-high expressing ccRCC.
    Journal
    |
    IL6 (Interleukin 6) • PIM1 (Pim-1 Proto-Oncogene)
    |
    Jakafi (ruxolitinib)
    2d
    Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=42, Recruiting, City of Hope Medical Center | Suspended --> Recruiting | Trial completion date: Jun 2029 --> Jun 2028 | Trial primary completion date: Jun 2029 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CXCL9 (Chemokine (C-X-C motif) ligand 9) • MMP3 (Matrix metallopeptidase 3)
    |
    Jakafi (ruxolitinib)
    3d
    MPOH14: A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. (2025-524302-15-00)
    P1/2, N=6, Not yet recruiting, MaaT PHARMA
    New P1/2 trial
    |
    Jakafi (ruxolitinib) • Xervyteg (MaaT013)
    5d
    Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2032 | Trial primary completion date: Mar 2026 --> Mar 2032
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib)
    6d
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    7d
    Rux-cALL-Pol 2020: Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. (2024-518316-39-00)
    P2/3, N=25, Recruiting, Medical University Of Lodz | Not yet recruiting --> Recruiting
    Enrollment open
    |
    JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    KMT2A rearrangement
    |
    cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • vindesine
    8d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2030 --> Jun 2030 | Trial primary completion date: Jan 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    13d
    Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Utah
    New P1 trial • Tumor mutational burden
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • Besremi (ropeginterferon alfa-2b-njft)
    14d
    Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency. (PubMed, Haematologica)
    Not available.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    14d
    INCA34176-254: A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jakafi (ruxolitinib) • prednisone • Niktimvo (axatilimab-csfr)